For your heavily pretreated patients with (CPS ≥1)
3L = third line; CI = confidence interval; CPR = combined positive score; CR = complete response; DOR = duration of response; GEJ = gastroesophageal junction; MMR = mismatch repair; MSI = microsatellite instability; MSI-H = microsatellite instability-high; MSS = microsatellite stable; ORR = overall response rate; PD-1 = programmed death receptor-1; PD-L1 = programmed death ligand 1; PR = partial response.
- Assessment of tumor status was performed every 6 to 9 weeks.
- Previous treatment must have included a fluoropyrimidine and platinum doublet.
- HER2/neu-positive patients must have previously received treatment with approved HER2/neu-targeted therapy.
- Patients with active autoimmune disease or a medical condition that required immunosuppression or with clinical evidence of ascites by physical exam were ineligible.
Major efficacy outcome measures
- ORR (according to RECIST v1.1 as assessed by BICR)
- DOR
aThat was symptomatic, rapidly progressive, required urgent intervention, occurred with a decline in performance status, or was confirmed at least 4 weeks later with repeat imaging.
Q3W = every 3 weeks; HER2/neu = human epidermal growth factor receptor 2; RECIST v1.1 = Response Evaluation Criteria In Solid Tumors v1.1; BICR =
blinded independent central review.
- Patients had MSS tumor status or undetermined MSI or MMR status.
bPD‑L1 status was determined using the PD‑L1 IHC 22C3 PharmaDx Kit.
cIn the recurrent or metastatic setting.
ECOG PS = Eastern Cooperative Oncology Group performance status.
Category 2A = Based upon lower-level evidence, there is uniform National Comprehensive Cancer Network® (NCCN®) consensus that the intervention is appropriate.1,2
NCCN makes no warranties of any kind whatsoever regarding their content, use, or application and disclaims any responsibility for their application or use in any way.
Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Gastric Cancer v.2.2020 and for Esophageal and Esophagogastric Cancer v.2.2020. © National Comprehensive Cancer Network, Inc. 2020. All rights reserved. Accessed May 14, 2020. To view the most recent and complete version of the guideline, go online to NCCN.org.
Consider another treatment option for all appropriate patients with gastric or GEJ cancer